Ozempic Weight Loss Results: How Much Do People Actually Lose?
Ozempic Weight Loss Results: How Much Do People Actually Lose?
The Short Answer
- Average loss in the pivotal STEP 1 trial was 14.9% of body weight on once-weekly semaglutide 2.4 mg over 68 weeks, versus 2.4% on placebo. [1]
- About 86% hit at least 5% weight loss, 69% hit 10%, half reached 15%, and 32% reached 20%+. Individual response varies widely. [1]
- Results sustain for at least two years on continued therapy — STEP 5 showed 15.2% loss maintained at 104 weeks. [2]
- Stopping the drug reverses most of the loss — people who switched to placebo after a 20-week run-in regained 6.9% over the next 48 weeks, while those who continued lost an additional 7.9%. [3]
- Tirzepatide (Mounjaro/Zepbound) outperforms semaglutide head-to-head — 20.2% vs 13.7% at 72 weeks in SURMOUNT-5. [12]
The single most common question in every Ozempic, Wegovy, and Mounjaro community is some version of "how much will I actually lose?" — and right behind it, "how long is this going to take?" The good news is the numbers are unusually well-studied for a weight-loss drug. We have huge clinical trials with tens of thousands of patients tracking exactly this. The picture: meaningful weight loss, slower than the dramatic before-and-after photos suggest, and very dependent on whether you keep taking the medication.
This comparison trap is real. The people who post on Reddit are usually the ones with dramatic results worth posting — that's survivorship bias. The trial data tells a more accurate story and helps you figure out where you actually fall on a realistic distribution, instead of comparing yourself to the one outlier success post you saw this morning.
What does the research actually say?
The benchmark study is called STEP 1. It enrolled 1,961 adults with overweight or obesity but without diabetes, and gave them either weekly semaglutide (the drug in Ozempic and Wegovy) at the 2.4 mg dose, or a placebo, for 68 weeks. The average weight loss in the medication group was 14.9% of body weight, compared to 2.4% in the placebo group.[1]
For a 250-pound person, that 14.9% works out to about 37 pounds lost over 16 months. The trial also reported how many people hit specific milestones: about 86% lost at least 5% of starting weight, 69% lost 10%, half lost 15%, and 32% lost 20% or more.[1]
STEP 1 patients reached 20%+ body weight loss
About 32% of participants on semaglutide 2.4 mg lost a fifth or more of their starting body weight at the 68-week mark — the upper end of typical response.[1]
The STEP 1 weight curve reaches its low point around week 60 — and holds for at least two years on continued treatment.
Why is the Ozempic dose different from these trial numbers?
"Ozempic" is the brand name for semaglutide approved for type 2 diabetes. It comes in doses of 0.5, 1.0, and 2.0 mg per week. The clinical trials above used the higher 2.4 mg dose — that's the dose branded as Wegovy specifically for weight loss. If you're prescribed Ozempic at 1.0 or 2.0 mg "off-label" for weight loss, expect somewhat less than the trial averages above, because you're on a smaller dose.[1]
Do the results last?
Yes — as long as you keep taking the drug. The two-year STEP 5 trial followed 304 people on semaglutide for 104 weeks and saw a sustained 15.2% average weight loss.[2] The much larger SELECT trial followed 17,604 adults with heart disease for about 4 years and saw 10.2% average loss on semaglutide versus 1.5% on placebo.[4] That's the longest-term randomized weight data we have, and it shows the loss holds.
What about the lifestyle factor?
Combining the medication with structured diet and activity coaching produces a small but real boost. STEP 3 added intensive behavioral therapy to semaglutide in 611 adults and saw 16.0% mean loss versus 5.7% with placebo plus the same coaching.[8] The extra 1 to 2 percentage points over the standard STEP 1 result is the value of structured lifestyle support layered on top of the drug. SURMOUNT-3 ran a similar design for tirzepatide and saw the most dramatic separation in the literature: patients who completed a 12-week lifestyle lead-in then went on tirzepatide lost an additional 18.4% over the next 72 weeks, while the placebo arm regained 2.5% over the same period.[11]
What if I have type 2 diabetes?
People with type 2 diabetes lose less weight on the same drug than people without diabetes — typically about 70% of the non-diabetic average. In SURMOUNT-2, tirzepatide at the 15 mg dose produced 14.7% mean loss in adults with type 2 diabetes versus the 20.9% seen in SURMOUNT-1's non-diabetic population.[10][9] Calibrate accordingly — the drug still works, just at a more modest magnitude.
Where does Reddit wisdom miss the mark?
Myth 1: "30 pounds in three months is normal"
What people say: Scrolling viral success posts at the 90-day mark makes it feel like losing 25 to 35 pounds in three months is typical.
What do the actual three-month numbers look like?
STEP 1's weight-loss curve reaches its nadir at around week 60 — the bulk of the loss happens over a year, not three months.[1] The first 16 weeks are dose escalation, which produces less loss than the maintenance phase that follows. The mean trial result of 14.9% at 68 weeks averages out to about 2.3 pounds per month for a 250-pound starting weight. The 30-pounds-in-90-days posts are the right tail of the distribution, often combined with aggressive dieting or higher starting weights (where percentages translate to bigger pound numbers). Comparing yourself to those will frustrate you.
Myth 2: "The weight will stay off if I stop"
What people say: The medication "resets your set point" and once you hit goal weight you can quit and the loss will stick.
What does the discontinuation research show?
The STEP 4 trial was designed specifically to answer this question. Researchers took 803 people who had lost about 11% of body weight on semaglutide, then randomly switched half to placebo. Over the next 48 weeks, the people who kept taking semaglutide lost another 7.9% — and the ones who switched to placebo regained 6.9%.[3] Stopping the drug causes regain. Plan for long-term therapy, or for a substantial maintenance protocol when you stop.
Myth 3: "Mounjaro always wins, so Ozempic is pointless"
What people say: Tirzepatide (Mounjaro/Zepbound) is universally better, so semaglutide is a waste.
What does the head-to-head trial actually show?
The SURMOUNT-5 trial directly compared tirzepatide to semaglutide in 751 adults over 72 weeks. Tirzepatide won — 20.2% versus 13.7% mean weight loss.[12] A real-world JAMA analysis of 18,386 matched patients also favored tirzepatide.[13] But 13.7% mean loss on semaglutide is still a major, clinically meaningful result. "Always wins" is wrong — and individual response varies enormously regardless of which drug.
What should you actually do?
Use 5%, 10%, 15%, and 20% of starting weight as your goals. That matches how the clinical trials report data, and it removes unfair comparisons with people at different starting weights.
Example: at 230 lbs, 5% = ~11.5 lbs, 10% = 23 lbs, 15% = ~35 lbs.
The first ~16 weeks are dose escalation and produce less loss. After that, the typical rate is 1 to 2 pounds per week. Anything dramatically faster is short-term water shifts. Anything dramatically slower over a 4 to 6 week stretch is worth talking to your doctor about.
If you haven't lost at least 5% by 12 to 16 weeks on the full dose, you may be a "non-responder" — a clinical rule of thumb used in obesity-medicine practice. Switching to tirzepatide is the most evidence-supported next step — SURMOUNT-5 showed 20.2% loss on tirzepatide versus 13.7% on semaglutide head-to-head.[12]
Have a real conversation with your doctor about cost, supply, and what happens when you stop. STEP 4 shows stopping cold causes regain.[3] The realistic plan is long-term, possibly at a lower maintenance dose.
A DEXA scan every few months tells you fat versus muscle. Many "plateaus" are visible at the waist long before the scale moves again.
What would your doctor tell you?
Your doctor is tracking the things that matter most: weight trend, blood pressure, blood sugar, cholesterol. Those numbers are probably moving in the right direction. The trial averages above are the foundation for the realistic-expectations conversation your doctor likely opens with.
Dose-day tip: If you're on a weekly injection, hunger usually returns slightly around days 5 to 7 — that's called dose fade. If you're on the daily pill form (Rybelsus), suppression peaks within a few hours of your morning dose. Plan high-protein meals around your hungry days either way.
When the scale stalls: The three biggest fixable causes are (1) underestimating food intake — most people underestimate by 20%+, (2) sleep below 6.5 hours, and (3) not enough resistance training. These three explain most plateaus before anyone needs to change medication.
A reality check: Roughly 14% of people in STEP 1 didn't even reach 5% weight loss in 68 weeks.[1] If you're in that group, you're not failing — you're a non-responder, and the evidence-based move is to talk to your doctor about switching drugs.
The most common question in every GLP-1 community is some variant of "how much will I actually lose?" — and right behind it, "how long will it take?" The numbers behind those questions are unusually well-characterized for a weight-loss intervention. Five large randomized trials in the STEP program plus the SELECT cardiovascular outcomes trial give us about 22,000 patient-years of semaglutide weight data. The picture is consistent: meaningful loss, slower than the before-and-after photos suggest, and highly dependent on whether you keep taking the drug.
The community comparison trap is real. Survivorship bias in GLP-1 subreddits means the loudest stories are the rapid losers. The trial data tells a more accurate story.
What does the research actually show?
The benchmark is STEP 1, the 68-week phase 3 trial of once-weekly semaglutide 2.4 mg in 1,961 adults with overweight or obesity but without diabetes. The treatment-policy primary endpoint was 14.9% mean weight loss versus 2.4% on placebo (difference -12.4 pp; 95% CI -13.4 to -11.5; P<0.001).[1] About 86.4% achieved ≥5% loss, 69.1% reached ≥10%, 50.5% reached ≥15%, and 32.0% hit ≥20%.[1] Both arms received counseling for a 500 kcal/day deficit diet plus 150 min/week of physical activity.[1]
The treatment-policy estimand is the conservative number. The secondary "trial-product estimand" — modeling outcomes if all participants had fully adhered — showed 16.9% mean loss.[1] If you adhere well, the higher number is the better forecast for your individual response.
How is the dose in STEP 1 different from the Ozempic label?
"Ozempic" is the brand name for semaglutide approved for type 2 diabetes at maintenance doses of 0.5, 1.0, or 2.0 mg weekly. The STEP 1 trial used the higher 2.4 mg dose, which is the dose branded as Wegovy for chronic weight management. People prescribed Ozempic off-label for weight loss may run at 1.0 or 2.0 mg, which produces less weight loss than the 2.4 mg results. The STEP 1 secondary trial-product estimand showed 16.9% mean loss at 68 weeks.[1]
of STEP 1 participants reached 20%+ body weight loss
Specifically, 32% lost 20% or more of starting body weight at 68 weeks on semaglutide 2.4 mg — the upper end of the response distribution, often achieved without supplementary structured exercise programs.[1]
Sustained loss at two years (STEP 5)
The two-year STEP 5 trial randomized 304 adults to semaglutide 2.4 mg or placebo for 104 weeks. Treatment policy mean weight loss was 15.2% versus 2.6% placebo (difference -12.6 percentage points; 95% CI -15.3 to -9.8; P<0.0001).[2] The 77.1% achieving 5% and 61.8% achieving 10% loss at two years suggests the trajectory plateaus after roughly a year but the loss is not transient under continued therapy.[2]
The STEP 1 weight-loss curve reaches its nadir around week 60, then holds with continued treatment for at least two years.
The cardiovascular cohort (SELECT)
SELECT studied 17,604 adults with established cardiovascular disease and obesity for an average of about 4 years — the longest randomized weight data we have. Mean weight loss at week 208 was 10.2% on semaglutide versus 1.5% on placebo; among adherent patients, loss reached 11.7%.[4] The cohort was older and predominantly male (mean age 61.6, 72.3% male), which partly explains the lower percentages relative to STEP — but it confirms the loss does not unwind over multi-year horizons on therapy.
The lifestyle multiplier (STEP 3 and SURMOUNT-3)
STEP 3 added intensive behavioral therapy to semaglutide in 611 adults. Mean loss reached 16.0% versus 5.7% with placebo plus IBT, with 86.6% hitting 5% or more.[8] SURMOUNT-3 enrolled 579 adults in a 12-week lifestyle lead-in, then randomized them: the tirzepatide arm lost an additional 18.4% from randomization to week 72 while the placebo arm regained 2.5% — a 20.8-percentage-point separation.[11] Pharmacotherapy preserves lifestyle gains far better than lifestyle alone.
The type 2 diabetes population
People with type 2 diabetes consistently lose less weight on the same drug than people without diabetes. SURMOUNT-2 tested tirzepatide in 938 adults with type 2 diabetes and obesity. The 15 mg dose produced 14.7% mean loss versus 3.2% on placebo — meaningful, but below the 20.9% seen in SURMOUNT-1's non-diabetic population.[10][9] If you have diabetes, calibrate expectations to roughly 70% of non-diabetic trial averages.
How wide is the individual variability?
The 14.9% mean is a population average, not a personal forecast. The distribution behind it is the part that prescribers wish patients understood better. In STEP 1, the response spread was approximately:
The placebo arm in STEP 1 also showed meaningful distribution: 31.5% achieved ≥5% loss, 12.0% achieved ≥10%, and 1.7% achieved ≥20%.[1] The right tail of placebo response is small, but it exists — a reminder that the "all of this is just the drug" framing is incomplete. Trial protocols include lifestyle counseling, and motivated patients respond.
What are the known predictors of stronger or weaker response?
The clearest predictor in the labeled use of these drugs is early response: a common clinical rule of thumb is that people who hit 5% loss by week 12 to 16 of maintenance dosing are likely to be responders. Higher baseline BMI tends to produce larger absolute pound loss but similar percentage loss. The single biggest negative predictor is treatment discontinuation — in STEP 1, 18.9% of semaglutide participants discontinued the drug, which is why the conservative treatment-policy estimate (-14.9%) is roughly 2 percentage points below the adherent-population estimate.[1]
Where does community wisdom diverge from research?
Reddit lore is mostly directionally right but quantitatively off. The three corrections that matter most:
Myth 1: "30 pounds in three months is normal"
Community belief: Six-figure-upvote success posts at 90-day milestones make it feel like dropping 25 to 35 pounds by month three is the median.
What does the trial data actually show for the 3-month mark?
STEP 1's published weight-loss curve reaches its nadir at approximately week 60 — meaning the bulk of the loss occurs over a year-plus, not 90 days.[1] The first 16 weeks are dose escalation, which produces less loss than the maintenance phase that follows. For a 250-pound starting weight, the trial mean of -14.9% at 68 weeks works out to ~37 pounds over 16 months — about 2.3 pounds per month averaged across the whole trial.[1] The 30-pounds-in-90-days posts represent the right tail of the distribution, often paired with aggressive caloric restriction, starting weights above 300 pounds (where percentages translate to bigger pound numbers), or early water-weight shifts. Comparing your trajectory to those posts will systematically frustrate you.
Myth 2: "Tirzepatide always wins"
Community belief: Mounjaro/Zepbound is universally superior, so semaglutide is a waste of time.
What does the head-to-head evidence actually show?
SURMOUNT-5 directly compared maximum tolerated dose tirzepatide to maximum tolerated dose semaglutide in 751 adults with obesity but no diabetes over 72 weeks. Tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide — a 6.5-percentage-point difference favoring tirzepatide (95% CI -8.1 to -4.9; P<0.001).[12] A real-world JAMA analysis of 18,386 propensity-matched new initiators reached similar conclusions: 81.8% of tirzepatide users reached 5% loss within a year versus 66.5% on semaglutide (HR 1.76; 95% CI 1.68–1.84).[13] But "always wins" is wrong — 13.7% mean loss on semaglutide is a meaningful, clinically significant result, and individual response varies enormously. About 32% of SURMOUNT-1 tirzepatide patients reached 25%+ loss; on semaglutide, that fraction is closer to 14%.[9]
Myth 3: "The loss is permanent"
Community belief: The medication "resets" your set point; you can come off after hitting goal and the loss will stick.
What does the discontinuation evidence show?
STEP 4 enrolled 803 adults who had completed a 20-week semaglutide run-in (losing about 10.6% on average) and randomized them to continue on 2.4 mg or switch to placebo for 48 more weeks. The continuation group lost an additional 7.9% from week 20 to week 68. The placebo-switch group regained 6.9% over the same window — a 14.8-percentage-point separation (95% CI -16.0 to -13.5; P<0.001).[3] Cardiovascular markers and waist circumference regressed in parallel.[3] The interpretation is unambiguous: discontinuation produces regain. Plan for indefinite therapy or for a substantial maintenance protocol when you stop.
Practical protocol for setting realistic expectations
Set milestone goals of 5%, 10%, 15%, and 20% of starting weight. These are the same milestones used in clinical trials, which makes comparison to published data straightforward and removes the comparison trap with people at different starting weights.
Example: at 230 lbs starting weight, 5% = ~11.5 lbs, 10% = 23 lbs, 15% = ~35 lbs, 20% = 46 lbs.
In the STEP trials, after the 16- to 17-week dose-escalation phase, the weekly average rate of loss for responders is roughly 1 to 2 pounds. Anything faster is short-term water shifts; anything slower over a 4- to 6-week rolling average is worth a conversation with your prescriber about dose, sleep, protein, or another barrier.
A common clinical rule of thumb defines a non-responder as failing to reach 5% loss by 12 to 16 weeks on the maintenance dose. If you're a non-responder, switching to tirzepatide is the most evidence-supported next step — SURMOUNT-5 showed 20.2% loss on tirzepatide versus 13.7% on semaglutide head-to-head.[12]
Talk to your prescriber about long-term cost, supply, and what happens if you stop. Have an off-ramp plan that includes structured nutrition, resistance training, and possibly a lower maintenance dose rather than abrupt discontinuation. STEP 4 makes clear that stopping cold is associated with significant regain.[3]
A DEXA scan every 3 to 6 months separates fat loss from lean mass loss. Many "plateaus" on the scale are recomposition — visible at the waist and in clothing sizes long before the scale moves again.
How do other populations and doses compare?
The STEP 1 number (-14.9%) is the most-quoted, but it's one data point in a wider mosaic:
| Trial | Population | Duration | Mean loss |
|---|---|---|---|
| STEP 1[1] | Adults, no diabetes (n=1,961) | 68 weeks | -14.9% |
| STEP 3[8] | Adults + intensive behavior therapy (n=611) | 68 weeks | -16.0% |
| STEP 5[2] | Adults, two-year (n=304) | 104 weeks | -15.2% |
| STEP 6[6] | East Asian adults (n=401) | 68 weeks | -13.2% |
| STEP TEENS[7] | Adolescents 12–17 (n=201) | 68 weeks | -16.1% BMI |
| STEP 8[5] | Sema 2.4 vs liraglutide 3.0 (n=338) | 68 weeks | -15.8% vs -6.4% |
| SELECT[4] | CV disease, mostly male (n=17,604) | 208 weeks | -10.2% |
| SURMOUNT-5[12] | Tirzepatide head-to-head (n=751) | 72 weeks | -13.7% sema vs -20.2% tirz |
Why does the East Asian cohort show less weight loss?
STEP 6 enrolled 401 Japanese and South Korean adults at lower baseline BMI (mean ~33) than the global STEP trials. The 13.2% loss on semaglutide 2.4 mg versus 2.1% on placebo (-11.1 percentage points; P<0.0001) reflects a smaller absolute weight pool to lose from, not a population-specific drug failure.[6] Visceral fat reductions were similarly large (40% reduction on 2.4 mg).[6]
Special populations: adolescents
STEP TEENS extended the program to adolescents 12 to 17 years old with obesity. The 201-participant trial measured change in BMI rather than absolute weight as the primary endpoint, because adolescents are still growing. The semaglutide group's BMI fell 16.1% versus a 0.6% increase in the placebo group over 68 weeks (difference -16.7 percentage points; 95% CI -20.3 to -13.2; P<0.001).[7] The magnitude is similar to adult trials, which is notable — many adult weight loss drugs underperform in adolescents.
What would your doctor tell you?
Your prescriber is tracking weight, blood pressure, HbA1c, and lipids. The depth that's hard to fit into a 15-minute visit is the variability — the 14.9% mean comes from a distribution where roughly 14% of STEP 1 patients did not reach 5% loss.[1]
Dose-day eating: If you're on a weekly injection, peak appetite suppression typically lands 24 to 48 hours post-injection, with hunger returning slightly by days 5 to 7 — the well-known dose-fade pattern. If you're on daily oral semaglutide (Rybelsus), the suppression cycle is much shorter — typically a few hours after the morning pill, with hunger returning by evening. Front-load high-protein meals during your hungriest window of the day regardless of which dosing form you're on.
The early-weeks trap: The first 4 weeks of titration produce less weight loss than people expect because the drug isn't at full effect yet. The standard escalation is 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg from week 17 onward.[1] The temptation to escalate faster or stack with other interventions creates side-effect burden that limits long-term adherence. Wait until at least the 1.7 mg or full 2.4 mg dose before judging your response.
A useful diagnostic when stalled: If you've plateaued for 6+ weeks at a stable maintenance dose, the highest-yield workup is a 7-day food log (most people underestimate intake by 20%+), a sleep audit (less than 6.5 hours per night significantly blunts weight loss), and a check of resistance training frequency (lean mass changes can shift body composition without scale movement). These three cover the majority of stalled-response cases without changing medication. If those check out and you're still stalled, the next clinical conversation is dose verification (are you actually on the maintenance dose, or did your prescriber hold you at 1.0 mg?) and finally drug switching if you've completed an honest 12 to 16 week trial at full dose.[12]
The maintenance reality: The STEP 4 data quietly reframes how to think about these drugs.[3] They are not a finite course of treatment like an antibiotic — they are an ongoing therapy more like a blood pressure medication. The 6.9% regain after 48 weeks off the drug suggests the underlying biology of weight regulation reasserts itself once the medication is gone, regardless of how disciplined the patient is. Building a realistic financial and access plan for indefinite therapy is part of starting these drugs responsibly.
Get the GLP-1 Guide for This Topic
Our research-backed guide covering key findings, practical strategies, and evidence-based recommendations from the studies cited in this article.
Free PDF · No spam · Unsubscribe anytime
Clinical citations
- Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." N Engl J Med. 2021;384(11):989-1002. Full text
- Garvey WT, Batterham RL, Bhatta M, et al. "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial." Nat Med. 2022;28(10):2083-2091. Full text
- Rubino D, Abrahamsson N, Davies M, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Randomized Clinical Trial." JAMA. 2021;325(14):1414-1425. Full text
- Ryan DH, Lingvay I, Deanfield J, et al. "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial." Nat Med. 2024;30(7):2049-2057. Full text
- Rubino DM, Greenway FL, Khalid U, et al. "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight: The STEP 8 Randomized Clinical Trial." JAMA. 2022;327(2):138-150. Full text
- Kadowaki T, Isendahl J, Khalid U, et al. "Semaglutide once a week in adults with overweight or obesity in an east Asian population (STEP 6)." Lancet Diabetes Endocrinol. 2022;10(3):193-206. Full text
- Weghuber D, Barrett T, Barrientos-Pérez M, et al. "Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS)." N Engl J Med. 2022;387(24):2245-2257. Full text
- Wadden TA, Bailey TS, Billings LK, et al. "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight: The STEP 3 Randomized Clinical Trial." JAMA. 2021;325(14):1403-1413. Full text
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." N Engl J Med. 2022;387(3):205-216. Full text
- Garvey WT, Frias JP, Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)." Lancet. 2023;402(10402):613-626. Full text
- Wadden TA, Chao AM, Machineni S, et al. "Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial." Nat Med. 2023;29(11):2909-2918. Full text
- Aronne LJ, Horn DB, le Roux CW, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)." N Engl J Med. 2025;393(1):26-36. Full text
- Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. "Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity." JAMA Intern Med. 2024;184(9):1056-1064. Full text
Get the GLP-1 Guide for This Topic
Key findings, practical strategies, and evidence-based recommendations — backed by the clinical studies cited above. Free PDF, straight to your inbox.
Free PDF · No spam · Unsubscribe anytime
Medical disclaimer
MetaBa content is educational and does not replace medical advice, diagnosis, or treatment from a licensed clinician. Always consult with your healthcare provider before making changes to your diet, exercise, or medication regimen.
Methodology: Community insights synthesized from 2,100+ posts across r/Ozempic, r/Mounjaro, r/Zepbound, r/GLP1, and r/semaglutide. Clinical claims cite peer-reviewed research with linked sources. Reddit quotes paraphrased and anonymized per platform terms.
